Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cuts
Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cuts gmasson Fri, 04/12/2024 - 11:07
Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cuts gmasson Fri, 04/12/2024 - 11:07
Portage Biotech hints at potential closure as it halts programs, hunts for strategic options mbayer Fri, 04/12/2024 - 10:33
Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis ntaylor Fri, 04/12/2024 - 09:31
Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing jwaldron Fri, 04/12/2024 - 06:26